Bioventus vs Glaukos
BVS and GKOS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BVS and GKOS compare
Glaukos is the larger company, worth 16 times as much as Bioventus ($14.6B against $924M).
Glaukos grew revenue faster over the last twelve months (46.9% versus 3.9% for Bioventus).
Bioventus keeps more of each dollar of sales as profit, with a net margin of 9.8% compared with −24.6% at Glaukos.
Bioventus scores higher on the StockData Score (14 against 7 for Glaukos), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BVS | GKOS |
|---|---|---|
| Size and price | ||
| Market cap | $924M | $14.6B |
| Share price | $10.99 | $247.16 |
| Change, 1 year | 46.7% | 180% |
| Change, 5 years | −21.6% | 414% |
| Beta (5Y) | 0.91 | 1.02 |
| Employees | 930 | 1,094 |
| StockData Score | ||
| Total score | 14 (better) | 7 |
| Valuation score | 4 (better) | 0 |
| Growth score | 3 | 3 |
| Performance score | 5 (better) | 2 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 13.7× | – |
| P/S | 1.6× (better) | 21.2× |
| P/B | 3.8× (better) | 20.4× |
| EV/EBITDA | 14.4× | – |
| P/FCF | 10.9× (better) | 406× |
| FCF yield | 9.2% (better) | 0.25% |
| Fair value | $16.36 | $77.32 |
| Margin of safety | 32.8% (better) | −220% |
| Growth | ||
| Revenue growth (TTM) | 3.9% | 46.9% (better) |
| Revenue growth, 5Y average | 12.1% | 17.7% (better) |
| Net income growth (TTM) | 655% | – |
| EPS growth (TTM) | 627% | – |
| Profitability | ||
| Gross margin | 68.7% (better) | 64.8% |
| Operating margin | 9.7% (better) | −25.5% |
| Net margin | 9.8% (better) | −24.6% |
| FCF margin | 14.5% (better) | 5.2% |
| Return on equity | 28.2% (better) | −22.8% |
| Return on invested capital | 12.8% (better) | −22.8% |
| Financial health | ||
| Debt / equity | 0.96 | – |
| Net debt / EBITDA | 2.44 | – |
| Interest coverage | – | −36.6× |
| Current ratio | 1.68 | 4.57 (better) |
| Altman Z-score | 2.19 | 32.75 (better) |
| Piotroski F-score | 8 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −0.31% | – |
| Shareholder yield | −0.31% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 71.2% | 103% |
| Held by insiders | 29.0% | 5.3% |
| Insider net buying, 12 months | −$181K (better) | −$78.8M |
| Short interest, % of float | 5.1% | 8.0% |
Go deeper
- BVS stock overview
- BVS income statement
- BVS valuation and score
- GKOS stock overview
- GKOS income statement
- GKOS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.